Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY TruVu
Lantheus Holdings has announced that the Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through status for its PSMA PET imaging agent PYLARIFY TruVu (piflufolastat F 18). This designation, as well as a permanent HCPCS code coming into effect on October 1, 2026, aims to enhance patient access and reimbursement for the imaging agent.
Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus’ PSMA PET imaging agent BEDFORD, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the